Schistosomiasis is a life threatening disease caused by blood flukes from the genus Schistosoma and despite effective and low cost chemotherapy is currently available, approximately 200 million people worldwide are infected with this parasite and other 600 million people are at risk of being infected. Furthermore, failure in treatment with praziquantel has been reported recently indicating the development of resistant parasites. As a result, developing of a vaccine would be an important advance on the control of this disease. It is known that schistosomes are unable to replicate within the vertebrate host, this means that a vaccine, although desirable, does not need to have a sterilizing protection to provide a benefit. Sm14, a fatty-acid binding protein (FABP) from S. mansoni and one of the six vaccine candidates selected by the WHO for clinical trials, has been shown to reduce the worm burden in immunized mice.
A Genetic Fusion between Sm14 and CTB does not Reduce Schistosoma mansoni Worm Burden on Intranasally Immunized BALB/c Mice: Henrique Roman Ramos, Patricia Aoki Miyasato, Celso Raul Romero Ramos, Ana Paula de Mattos ArÃªas, Toshie Kawano3 and Paulo Lee Ho
Last date updated on January, 2021